Cardiogenic shock patients represent a wide spectrum of disease that requires tailored therapy to improve hemodynamic derangements. The intra-aortic balloon pump (IABP) has long been the first-line choice for mechanical circulatory support around the world due to its clinical efficacy, safety profile across a broad range of patient care scenarios. Despite the ability of newer mechanical circulatory support devices (MCS) to provide greater hemodynamic support, improved clinical outcomes have not been proven. The purpose of this session is to share experts experience on the use of IABP therapy in the treatment of ischemic and non-ischemic cardiogenic shock patients considering current clinical evidence.